Cambridge Investment Research Advisors’s Virpax Pharmaceuticals, Inc. Common Stock VRPX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio VRPX Stock Details VRPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-64	Closed	-$13K	–	3320
2023 Q1	$13K	Sell	64 -2	-3%	-$446	﹤0.01%	3126
2022 Q4	$10K	Sell	66 -1	-1%	-$228	﹤0.01%	3079
2022 Q3	$20K	Hold	67	–	–	﹤0.01%	3002
2022 Q2	$28K	Sell	67 -2	-3%	-$820	﹤0.01%	2980
2022 Q1	$38K	Sell	69 -2	-3%	-$1.17K	﹤0.01%	3096
2021 Q4	$61K	Sell	71 -7	-9%	-$7.21K	﹤0.01%	3084
2021 Q3	$93K	Buy	+78	New	+$163K	﹤0.01%	2966

Other funds holding VRPX

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

QPW

Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Cambridge Investment Research Advisors's VRPX Position: Q2 2023 in Review

Cambridge Investment Research Advisors sold out of Virpax Pharmaceuticals, Inc. Common Stock (VRPX) in Q2 2023, closing a stake of 64 shares — an estimated $13K sold.

Cambridge Investment Research Advisors first reported a position in VRPX in Q3 2021 and held it in 7 quarters. The position peaked at $93K in Q3 2021. 12 funds tracked by Wall St. Rank hold VRPX as of Q2 2023.

Cambridge Investment Research Advisors reported no remaining Virpax Pharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Cambridge Investment Research Advisors sold 64 Virpax Pharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $13K.
Cambridge Investment Research Advisors first reported a position in Virpax Pharmaceuticals, Inc. Common Stock in Q3 2021 and held it in 7 quarters.
Cambridge Investment Research Advisors's Virpax Pharmaceuticals, Inc. Common Stock position peaked at $93K in Q3 2021.
12 funds tracked by Wall St. Rank held Virpax Pharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2023, filed 13 Jul 2023.